CV Sciences, Inc. To Announce Second Quarter 2025 Results On August 13, 2025
CV Sciences (OTCQB:CVSI), a consumer wellness company focused on hemp extracts and natural ingredients, has scheduled its Q2 2025 earnings release for August 13, 2025 after market close.
The company will host a conference call with investors at 1:30 PM PT / 4:30 PM ET on the same day. Investors can access the webcast through the company's IR website or dial in directly. A replay will be available until August 20, 2025.
CV Sciences (OTCQB:CVSI), azienda del settore benessere focalizzata su estratti di canapa e ingredienti naturali, ha fissato la pubblicazione dei risultati del 2T 2025 per il 13 agosto 2025 dopo la chiusura dei mercati.
La società terrà una conference call con gli investitori lo stesso giorno alle 13:30 PT / 16:30 ET. Gli investitori potranno seguire il webcast tramite il sito IR della società o collegandosi telefonicamente. La replica sarà disponibile fino al 20 agosto 2025.
CV Sciences (OTCQB:CVSI), empresa de bienestar centrada en extractos de cáñamo e ingredientes naturales, ha programado la publicación de sus resultados del 2T 2025 para el 13 de agosto de 2025 tras el cierre del mercado.
La compañía celebrará una conferencia telefónica con inversores ese mismo día a las 1:30 PM PT / 4:30 PM ET. Los inversores podrán acceder al webcast a través del sitio de relaciones con inversores de la empresa o llamando directamente. La grabación estará disponible hasta el 20 de agosto de 2025.
CV Sciences (OTCQB:CVSI)는 햄프 추출물과 천연 성분에 주력하는 소비자 웰니스 기업으로, 2025년 8월 13일 장 마감 후에 2025년 2분기 실적을 발표할 예정입니다.
같은 날 투자자 대상 컨퍼런스 콜을 오후 1시 30분 PT / 오후 4시 30분 ET에 진행합니다. 투자자는 회사의 IR 웹사이트를 통해 웨비캐스트에 접속하거나 전화로 참여할 수 있으며, 재청취는 2025년 8월 20일까지 제공됩니다.
CV Sciences (OTCQB:CVSI), société de bien-être grand public axée sur les extraits de chanvre et les ingrédients naturels, a programmé la publication de ses résultats du 2e trimestre 2025 le 13 août 2025 après la clôture des marchés.
La société tiendra une conférence téléphonique avec les investisseurs le même jour à 13h30 PT / 16h30 ET. Les investisseurs pourront suivre le webcast via le site IR de la société ou se connecter par téléphone. Un replay sera disponible jusqu'au 20 août 2025.
CV Sciences (OTCQB:CVSI), ein Verbraucher-Wellness-Unternehmen mit Schwerpunkt auf Hanfextrakten und natürlichen Inhaltsstoffen, hat die Veröffentlichung der Ergebnisse für das 2. Quartal 2025 für den 13. August 2025 nach Börsende terminiert.
Am selben Tag veranstaltet das Unternehmen um 13:30 PT / 16:30 ET eine Konferenzschaltung für Anleger. Anleger können das Webcast über die IR-Website des Unternehmens verfolgen oder sich per Telefon einwählen. Eine Aufzeichnung steht bis zum 20. August 2025 zur Verfügung.
- None.
- None.
SAN DIEGO, CALIFORNIA / ACCESS Newswire / August 8, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the second quarter ended June 30, 2025, after the stock market closes on Wednesday, August 13, 2025. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day.
The webcast of the conference call will be available on the Investor Relations section of the Company's website at https://ir.cvsciences.com/news-events or directly at https://viavid.webcasts.com/starthere.jsp?ei=1727552&tp_key=38f7de0673. The webcast will be archived for approximately 30 days. Investors interested in participating in the live call can also dial (877) 407-0784 from the U.S. or international callers can dial (201) 689-8560. Please dial the conference telephone number 15 minutes prior to the start time due to increased demand for conference calls.
A telephone replay will be available approximately two hours after the call concludes and will be available through Wednesday, August 20, 2025, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 13754956.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces cannabinoid-free supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ brand provides a variety of
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties. CV Sciences does not undertake any obligation to publicly update any forward-looking statements, except as required by applicable law. As a result, investors should not place undue reliance on such forward-looking statements.
CONTACT INFORMATION:
SOURCE: CV Sciences, Inc.
View the original press release on ACCESS Newswire